- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- marstacimab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 1 Year to 17 Years · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- PF-06741086
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 1 Year to 74 Years · Male only
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Hemophilia A With Inhibitor, Hemophilia A
- Interventions
- Wilate
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Sacramento, California • San Diego, California • New Orleans, Louisiana
- Conditions
- HIV Infections, Hemophilia A
- Interventions
- Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years and older · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 7
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
- Conditions
- Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
- Interventions
- Valoctocogene roxaparvovec
- Biological
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- PF-06741086
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 74 Years · Male only
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Iowa City, Iowa • New Hyde Park, New York + 1 more
- Conditions
- Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
- Interventions
- Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Cleveland, Ohio